Status:
COMPLETED
COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
Lead Sponsor:
Institut Curie
Conditions:
Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over t...
Eligibility Criteria
Inclusion
- Person, adult volunteer outside of any acute infectious episode with SARS-CoV-2\* (see paragraph indication), working at the Institute Curie and able to exercise their professional activity on one of the 3 sites of the Institute Curie: Paris, Orsay or Saint Cloud, or on the Campus of the Institute Pasteur.
- Person aged 18 or over.
- Information and consent of the person to the procedures related to the study (cf. information note / consent).
- From November 2020, person having presented at least one of the following criteria since January 2020:
- A positive diagnostic test for SARS-COV-2 by PCR on a nasopharyngeal sample or antigenic test,
- A positive SARS-CoV-2 serology,
- An anosmia or / and an ageusia,
- A respiratory infection \*\* associated with digestive signs \*\*
- whatever the working methods during confinement \* Subjects who are not showing active SARS-CoV-2 infection are considered volunteers at the time of inclusion: people with no clinical signs \*\* suggestive of SARS-CoV-2 infection at the time of collection or having had an end of symptoms for more than 7 days \[1\].
- \*\* fever, fatigue, cough, shortness of breath, difficulty to breath, loss of taste or smell, headache, body aches, conjunctivitis or cold, digestive problems (vomiting, diarrhea), whether or not the signs led to sick leave, treatment and / or hospitalization \[2\].
Exclusion
- Declaration by the subject of signs suggestive of Coronavirus Infectious Disease 2019 (COVID-19) infection with SARS-CoV-2 in progress or for which the end of symptoms dates from less than 7 days
- Inability to submit to study monitoring for geographic, social or psychological reasons
Key Trial Info
Start Date :
April 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2022
Estimated Enrollment :
1971 Patients enrolled
Trial Details
Trial ID
NCT04369066
Start Date
April 28 2020
End Date
May 13 2022
Last Update
September 23 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie
Paris, France, 75005
2
Institut Pasteur
Paris, France, 75015